Stocklytics Platform
PTC Therapeutics
PTCT62
$52.76arrow_drop_down1.58%-$0.85
NASDAQ - As of Mar 14, 12:03 AM EDT Market Closed
PTCT62

$52.76

arrow_drop_down1.58%

Performance History

arrow_drop_up78.54%

(+$23.21 )

Stocklytics logo
Key Stats
Open$52.89
Prev. Close$53.61
EPS-4.73
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$4.35B
PE Ratio-
LOWHIGH
Day Range52.65
54.58
52 Week Range17.53
55.63

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Stocklytics logo

Period: Next 12 Months

Predicted: just now

info

Analyzed by 19 Wall Street experts, PTC Therapeutics 's 12-month projections average at $34.26, spanning from a high of $65.00 to a low of $17.00. This signifies an -35.05% shift from the current price of $52.76.

Analyst Ratings

Buy

Buy
9
60.00%
Hold
3
20.00%
Sell
3
20.00%
Ratings from: March

Last updated: just now

Total: 15
info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

Price$801.65
Perf. (24h)arrow_drop_down2.37%-$19.52
Market Cap$720.01B
Price$481.52
Perf. (24h)arrow_drop_up0.08%$0.40
Market Cap$444.64B
Price$162.99
Perf. (24h)arrow_drop_up0.08%$0.14
Market Cap$397.30B
Price$211.55
Perf. (24h)arrow_drop_down0.24%-$0.50
Market Cap$373.46B

About PTC Therapeutics (PTCT)

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of novel medicines for rare disorders. The company's product pipeline includes treatments for diseases such as Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA). PTC Therapeutics' lead product is Translarna, an oral medication for the treatment of DMD caused by a nonsense mutation. The company is also developing other therapies for SMA and rare genetic disorders. PTC Therapeutics is committed to bringing innovative therapies to patients with limited treatment options.
The stock price of PTC Therapeutics Inc (PTCT) has experienced fluctuations over the years. In the past, PTCT stock price has ranged from a low of $5.67 to a high of $66.95. The 52-week range for PTCT is $25.46 to $66.95. It is important to note that stock prices can be influenced by various factors, including market conditions, investor sentiment, and company news.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Matthew B. Klein F.A.C.S., FACS, M.D., M.S., MS
Headquarters
South Plainfield
Employees
1402
Exchange
NASDAQ
add PTC Therapeutics  to watchlist

Keep an eye on PTC Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is PTC Therapeutics 's (PTCT) price per share?

The current price per share for PTC Therapeutics (PTCT) is $52.76. The stock has seen a price change of -$0.85 recently, indicating a -1.59% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for PTC Therapeutics (PTCT)?

For PTC Therapeutics (PTCT), the 52-week high is $55.63, which is 5.45% from the current price. The 52-week low is $17.53, the current price is 200.97% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is PTC Therapeutics (PTCT) a growth stock?

PTC Therapeutics (PTCT) has shown an average price growth of -1.65% over the past three years. It has received a score of 79 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying PTC Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is PTC Therapeutics (PTCT) stock price performance year to date (YTD)?

As of the latest data, PTC Therapeutics (PTCT) has a year-to-date price change of 16.88%. Over the past month, the stock has experienced a price change of 7.83%. Over the last three months, the change has been 11.4%. Over the past six months, the figure is 61.35%. Looking at a longer horizon, the five-year price change stands at 26.52%.
help

Is PTC Therapeutics (PTCT) a profitable company?

PTC Therapeutics (PTCT) has a net income of -$363.3M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -7.45% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $806.78M, although specific revenue growth data is currently not available. The gross profit is $806.78M. Operating income is noted at -$302.57M. Furthermore, the EBITDA is $35.36M.
help

What is the market capitalization of PTC Therapeutics (PTCT)?

PTC Therapeutics (PTCT) has a market capitalization of $4.36B. The average daily trading volume is 53.13, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level